Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson announced that nipocalimab, an FcRn blocker, met its primary endpoint in the Phase 2 JASMINE study by significantly reducing systemic lupus erythematosus (SLE) disease activity at 24 weeks and sustained improvements through 52 weeks. The drug demonstrated greater efficacy in autoantibody-positive patients (80% of SLE population) with a favorable safety profile. The Phase 3 GARDENIA study is ongoing, and nipocalimab received Fast Track Designation from the FDA in January 2026.